Seeking Alpha

Exact Sciences down 2% after hours on Q4 revenue miss

|About: Exact Sciences Corpora... (EXAS)|By: , SA News Editor

Exact Sciences (NASDAQ:EXAS) Q4 results:

Revenue: $295.6M (+107%) (consensus: $297.6M) Screening: $229.4M

Cologuard test volume: 477K (+63%); average cost/test: $123 (-5%); average revenue/test: $481 (-1%).

Oncotype DX test volume: 41K (+13%).

Net income: $77.9M (+244%); EPS: $0.54 (+223%) [consensus: ($0.36)].

Non-GAAP EBITDA: $9.7M (+136%).

2020 guidance: Revenue: $1.610B - 1.645B (consensus: $1.59B); screening revenue: $1.125B - 1.150B; precision oncology: $485M - 495M.

Shares down 2% after hours.

EXACT Sciences EPS beats by $0.87, misses on revenue